Three former FDA officials — including ex-acting commissioner Janet Woodcock — told reporters this week that HHS Secretary Robert F. Kennedy Jr. mischaracterized their 2023 peptide-safety review as he pushes to reverse it. The statements, published by ProPublica and amplified in an April 29 STAT op-ed, land less than three months before the Pharmacy Compounding Advisory Committee is scheduled to vote on the remaining peptides.
What the former officials actually said
The dispute centers on the FDA's 2023 decision to move 19 peptides — including BPC-157, GHK-Cu, and epitalon — onto Category 2 of the interim 503A bulks list. Category 2 is the designation reserved for substances the agency considers to pose significant safety risks, blocking 503A pharmacies from compounding them.
Kennedy has called that decision "illegal" and said the underlying safety review was thin. The former officials disagree.
Janet Woodcock framed the stakes broadly: reversing the bans without new clinical evidence "would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S." She added that the bulks-list pathway "wasn't supposed to be a route for unapproved drugs to get into the market."
Two other former officials told ProPublica that Kennedy's framing — that the 2023 safety concerns were unfounded — would, if used to justify reversal, "give a false imprimatur of safety to more than a dozen unapproved, untested drugs." All three pointed out that essentially no new clinical data on the disputed peptides has emerged since the original review.
The procedural reality: April 22 already happened
A piece of the reversal is already done. The FDA pulled 12 of the 19 peptides off Category 2 effective April 22, 2026, because the original nominators voluntarily withdrew their petitions. That removal happened on procedural grounds — not because the FDA endorsed the safety profile of those peptides.
The remaining items go to PCAC on July 23-24, 2026. The advisory committee will hear public comment (the comment window closes mid-July), then issue a non-binding recommendation. The FDA then publishes its final decision, which can take months.
So the practical timeline:
- April 22, 2026: 12 peptides off Category 2 procedurally (already in effect).
- July 23-24, 2026: PCAC vote on the rest.
- Late 2026 or early 2027: Final FDA action.
Even after a favorable PCAC vote, peptides do not become FDA-approved drugs. They become eligible for compounding under physician prescription through a 503A pharmacy. They still lack approved labeling, standardized dosing, and the manufacturing oversight that branded drugs receive.
What this means if you're already buying peptides
The research-chemical market — where most readers of this site source — operates outside both Category 1 and Category 2. It did not pause for the 2023 reclassification, and it will not pause for the July vote. The regulatory uncertainty matters for compounding pharmacies and telehealth clinics. It does not change the math for someone evaluating a research-grade vendor.
What does change the math:
- COA quality. Independent third-party assays remain the only meaningful verification of peptide identity and purity. Vendors that publish full Janoshik or Acen reports for each batch beat vendors that publish only an in-house spec sheet. Our vendor scoring rubric weights this at 30%.
- Vendor reputation. Several large vendors have shut down in the last 12 months under FDA, FTC, or law-enforcement pressure — Peptide Sciences, Amino Asylum, Paradigm, and others. The running shutdown list is the single fastest credibility signal.
- Stock and shipping. Vendors with consistent inventory and tracked shipping outperform fly-by-night operations regardless of where the FDA lands. Live deals are tracked and updated as availability changes.
If you've been waiting for "regulatory clarity" before sourcing peptides, the honest read is that clarity isn't coming on the timeline you'd like. Even a clean July vote leaves the research-chemical channel untouched, and the compounding pathway requires a prescription either way.
